Drug repurposing for Dravet syndrome in scn1Lab^-/- mutant zebrafish.

ABSTRACT: Dravet syndrome (DS) is a severe genetic epileptic encephalopathy with onset during the first year of life. Zebrafish models recapitulating human diseases are often used as drug discovery platforms, but also for drug repurposing testing. It was recently shown that pharmacological modulation of three serotonergic (5-HT) receptors (5-HT_1D , 5-HT_2C , 5-HT_2A ) exerts antiseizure effects in a zebrafish scn1Lab^-/- mutant model of DS. Using the zebrafish DS model, our aim was to examine the possibility of repurposing efavirenz (EFA), lisuride (LIS), and rizatriptan (RIZA), marketed medicines with a 5-HT on- or off-target profile, as antiepileptic drugs for DS. To examine whether these compounds have a broader antiseizure profile, they were tested in pen

SUBMITTER: Sourbron J 

PROVIDER: S-EPMC6850687 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature